Outcomes of patients with chronic lymphocytic leukemia and Richter's transformation after transplantation failure

Journal of Clinical Oncology

Volumn 33, Issue 14, 2015, Pages 1557-1563

  Rozovski, Uri ^a   Benjamini, Ohad ^a   Jain, Preetesh ^a   Thompson, Philip A ^a   Wierda, William G ^a   O'Brien, Susan ^a   Burger, Jan A ^a   Ferrajoli, Alessandra ^a   Faderl, Stefan ^a   Shpall, Elizabeth ^a   Hosing, Chitra ^a   Khouri, Issa F ^a   Champlin, Richard ^a   Keating, Michael J ^a   Estrov, Zeev ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; HEMOGLOBIN; IBRUTINIB; IMMUNOGLOBULIN LIGHT CHAIN; LENALIDOMIDE; METHOTREXATE; METHYLPREDNISOLONE; OFATUMUMAB; OXALIPLATIN; PEGFILGRASTIM; PREDNISONE; PROTEIN P53; RITUXIMAB; THALIDOMIDE; VINCRISTINE; ANTINEOPLASTIC AGENT; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC LYMPHATIC LEUKEMIA; FATIGUE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENERAL CONDITION DETERIORATION; GRAFT FAILURE; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; GRANULOCYTOPENIA; HUMAN; IMMUNOTHERAPY; LEUKEMIA RELAPSE; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RECURRENT DISEASE; RECURRENT INFECTION; REMISSION; RETROSPECTIVE STUDY; RICHTER TRANSFORMATION; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT FAILURE; ALLOTRANSPLANTATION; CHRONIC DISEASE; DISEASE COURSE; FACTORIAL ANALYSIS; GRAFT VS HOST DISEASE; IMMUNOSUPPRESSIVE TREATMENT; KAPLAN MEIER METHOD; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MIDDLE AGED; PROCEDURES; RISK FACTOR; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CHRONIC DISEASE; DISEASE PROGRESSION; FACTOR ANALYSIS, STATISTICAL; FEMALE; GRAFT VS HOST DISEASE; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; PYRAZOLES; PYRIMIDINES; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84933500314     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.58.6750     Document Type: Article

References (38)

1. Hallek M, Fischer K, Fingerle-Rowson G, et al: Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: A randomised, open-label, phase 3 trial. Lancet 376:1164-1174, 2010
2. Keating MJ, O'Brien S, Albitar M, et al: Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 23:4079-4088, 2005
3. Montserrat E, Moreno C, Esteve J, et al: How I treat refractory CLL. Blood 107:1276-1283, 2006
4. Dreger P, European Group for Blood and Marrow Transplantation (EBMT): The evolving role of stem cell transplantation in chronic lymphocytic leukemia. Hematol Oncol Clin North Am 27:355-369, 2013
5. Gribben JG, Zahrieh D, Stephans K, et al: Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia. Blood 106:4389-4396, 2005
6. Khouri IF, Keating MJ, Saliba RM, et al: Longterm follow-up of patients with CLL treated with allogeneic hematopoietic transplantation. Cytotherapy 4:217-221, 2002
7. Khouri IF, Keating MJ, Vriesendorp HM, et al: Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: Preliminary results. J Clin Oncol 12:748-758, 1994
8. Khouri IF, Przepiorka D, van Besien K, et al: Allogeneic blood or marrow transplantation for chronic lymphocytic leukaemia: Timing of transplantation and potential effect of fludarabine on acute graft-versus-host disease. Br J Haematol 97:466-473, 1997
9. Malhotra P, Hogan WJ, Litzow MR, et al: Long-term outcome of allogeneic stem cell transplantation in chronic lymphocytic leukemia: Analysis after a minimum follow-up of 5 years. Leuk Lymphoma 49:1724-1730, 2008
10. Rabinowe SN, Soiffer RJ, Gribben JG, et al: Autologous and allogeneic bone marrow transplantation for poor prognosis patients with B-cell chronic lymphocytic leukemia. Blood 82:1366-1376, 1993
11. Dreger P, Brand R, Milligan D, et al: Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: A population-matched analysis. Leukemia 19:1029-1033, 2005
12. Sorror ML, Storer BE, Sandmaier BM, et al: Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. J Clin Oncol 26:4912-4920, 2008
13. Brown JR, Kim HT, Armand P, et al: Longterm follow-up of reduced-intensity allogeneic stem cell transplantation for chronic lymphocytic leukemia: Prognostic model to predict outcome. Leukemia 27:362-369, 2013
14. Dreger P, Döhner H, Ritgen M, et al: Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: Long-term clinical and MRD results of the German CLL Study Group CLL3X trial. Blood 116: 2438-2447, 2010
15. Khouri IF, Bassett R, Poindexter N, et al: Nonmyeloablative allogeneic stem cell transplantation in relapsed/refractory chronic lymphocytic leukemia: Long-term follow-up, prognostic factors, and effect of human leukocyte histocompatibility antigen subtype on outcome. Cancer 117:4679-4688, 2011
16. Sorror ML, Storer BE, Maloney DG, et al: Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia. Blood 111:446-452, 2008
17. Schetelig J, van Biezen A, Brand R, et al: Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: A retrospective European Group for Blood and Marrow Transplantation analysis. J Clin Oncol 26:5094-5100, 2008
18. Garnier A, Robin M, Larosa F, et al: Allogeneic hematopoietic stem cell transplantation allows longterm complete remission and curability in high-risk Waldenström's macroglobulinemia: Results of a retrospective analysis of the Société Française de Greffe de Moelle et de Thérapie Cellulaire. Haematologica 95:950-955, 2010
19. Ritgen M, Stilgenbauer S, von Neuhoff N, et al: Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: Implications of minimal residual disease measurement with quantitative PCR. Blood 104:2600-2602, 2004
20. Rondón G, Giralt S, Huh Y, et al: Graft-versusleukemia effect after allogeneic bone marrow transplantation for chronic lymphocytic leukemia. Bone Marrow Transplant 18:669-672, 1996
21. Khouri IF, Lee MS, Saliba RM, et al: Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: Impact of rituximab on immunomodulation and survival. Exp Hematol 32:28-35, 2004
22. Cheson BD, Bennett JM, Grever M, et al: National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment. Blood 87:4990-4997, 1996
23. Hallek M, Cheson BD, Catovsky D, et al: Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111:5446-5456, 2008
24. Khouri IF, Keating M, Körbling M, et al: Transplant-lite: Induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 16:2817-2824, 1998
25. Khouri IF, Saliba RM, Admirand J, et al: Graft-versus-leukaemia effect after non-myeloablative haematopoietic transplantation can overcome the unfavourable expression of ZAP-70 in refractory chronic lymphocytic leukaemia. Br J Haematol 137: 355-363, 2007
26. Garcia-Manero G, Kantarjian HM: The hyper- CVAD regimen in adult acute lymphocytic leukemia. Hematol Oncol Clin North Am 14:1381-1396, 2000
27. Tsimberidou AM, Wierda WG, Plunkett W, et al: Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 26:196-203, 2008
28. Marks DI, Lush R, Cavenagh J, et al: The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation. Blood 100:3108-3114, 2002
29. Mattsson J, Uzunel M, Remberger M, et al: Minimal residual disease is common after allogeneic stem cell transplantation in patients with B cell chronic lymphocytic leukemia and may be controlled by graft-versus-host disease. Leukemia 14:247-254, 2000
30. Moreno C, Villamor N, Colomer D, et al: Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia. Blood 107:4563-4569, 2006
31. Cwynarski K, van Biezen A, de Wreede L, et al: Autologous and allogeneic stem-cell transplantation for transformed chronic lymphocytic leukemia (Richter's syndrome): A retrospective analysis from the chronic lymphocytic leukemia subcommittee of the chronic leukemia working party and lymphoma working party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 30:2211-2217, 2012
32. Rodriguez J, Keating MJ, O'Brien S, et al: Allogeneic haematopoietic transplantation for Richter's syndrome. Br J Haematol 110:897-899, 2000
33. Tsimberidou AM, O'Brien S, Khouri I, et al: Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation. J Clin Oncol 24:2343-2351, 2006
34. Fabbri G, Khiabanian H, Holmes AB, et al: Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome. J Exp Med 210:2273-2288, 2013
35. Kharfan-Dabaja MA, Wierda WG, Cooper LJ: Immunotherapy for chronic lymphocytic leukemia in the era of BTK inhibitors. Leukemia 28:507-517, 2014
36. Byrd JC, Brown JR, O'Brien S, et al: Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 371:213-223, 2014
37. Dreger P, Schnaiter A, Zenz T, et al: TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: Six-year follow-up of the GCLLSG CLL3X trial. Blood 121:3284-3288, 2013
38. Woyach JA, Furman RR, Liu TM, et al: Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. N Engl J Med 370:2286-2294, 2014